Aktienanalyse zu ProMIS Neurosciences Inc (PMN)PMNProMIS Neurosciences Inc

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ProMIS Neurosciences Inc is not a good buy right now due to its extremely low RSI of 20.628, indicating oversold conditions, and a staggering 5-day price change of -62.78%. The stock is currently trading at $3.00, significantly below its 52-week high of $27.40, which raises concerns about its viability. While analysts have set a price target as high as $69, the recent performance and negative earnings reports suggest that risks outweigh potential rewards. The main risk is the company's ongoing losses, with a net income of -11,729,656 USD in Q2 2026, indicating financial instability.